NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...
NEW YORK, Aug. 29 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...
Plaintiff claims suffered damages in Korean Air Lines price fixing conspiracy SEATTLE, Aug. 10 /PRNewswire/ -- Seattle-based law firm Hagens Berman Sobol Shapiro filed a class action lawsuit...
NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases...
Company Cites Continuing Progress on Clinical and Preclinical Programs NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug...
NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company primarily focused on the development of new drugs to treat cancer and...
NEW YORK, June 25 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats...
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and...
NEW YORK, May 24 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drugs for the treatment of cancer and inflammatory diseases, announced today...
History of Atiprimod Appears in Genetic Engineering & Biotechnology News NEW YORK, May 15 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
4 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
12 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
26 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
52 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
156 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
260 | 0.06 | 75 | 0.08 | 0.16 | 0.08 | 1593 | 0.12165007 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관